key: cord-0079388-10zeqix1
authors: Olarte Carrillo, Irma; Ramos Peñafiel, Christian Omar; Mendoza Salas, Iveth; Cerón Maldonado, Rafael; García Laguna, Anel Irais; De la Cruz Rosas, Adrián; Martinez Murrillo, Carlos; Martinez Tovar, Adolfo
title: Impact of the ABCB1 Drug Resistance Gene on the Risk Factors of Patients with COVID-19 and Its Relationship with the Drugs Used
date: 2022-05-24
journal: Infect Drug Resist
DOI: 10.2147/idr.s358389
sha: e2351ff6ea5b97bc7957bbd177dbec7dffc484ea
doc_id: 79388
cord_uid: 10zeqix1

OBJECTIVE: In the last two years progress was made in molecular, physio pathological understanding and the form of transmission of COVID-19, and different therapeutic strategies have been explored to deal with the situation of the pandemic. However, the evaluation of certain genes that participate in the metabolism and transport of these drugs has not been fully explored. A lack of response to treatment and a lower survival have been observed that may be due to the presence of the ABCB1 drug resistance gene. Our research group analyzed whether the expression levels of the ABCB1 gene are associated with comorbidities, treatments, overall survival and risk of death in patients with severe COVID-19. METHODS: The expression levels of the ABCB1 gene were analyzed by RT-qPCR in 61 patients diagnosed with COVID-19. The association between the levels of expression, the risk variables and different treatments were determined by the Chi-Square test and the Fisher’s exact test. Global Survival (GS) was determined by the Kaplan–Meier method. The impact of high levels of expression and the risk of death was performed by odds ratio. RESULTS: The different risk variables showed that patients with either high or absent levels of ABCB1 gene expression presented a greater risk of death (OR 3.08, 95%, CI 1.02–9.26) as well as need for ventilatory support (OR 2.8, 95%, CI 0.98 −8.5). Patients with diabetes and COVID-19, treated with metformin, were associated with a lower risk of death (OR 1.11, 95%, CI 0.38–3.22). OS with respect to high or absent levels of expression of the ABCB1 gene was lower. CONCLUSION: High levels or null expression of the ABCB1 gene are associated with a higher risk of death or progression of the disease, the use of metformin in patients with COVID-19 confers a lower risk of death.

The incubation period of a COVID-19 infection is usually 1 to 14 days and can be extended up to 24 days. 7 The health conditions of most patients with COVID-19 are mild, but they can become serious, especially among the elderly or with underlying diseases, such as chronic or cardiovascular pulmonary disease. 8 Various factors such as male gender, diabetes, hypertension, alterations in blood counts and hypoalbuminemia have been associated with a rapid progression towards respiratory failure. 9, 10 Infection by other viruses such as influenza A or B can cause symptoms similar to those of COVID-19, which can complicate the distinction between this and other diseases, especially during the flu season. 11, 12 The current gold standard for the diagnosis of COVID-19 is based on the detection of the virus RNA in respiratory samples of nasopharyngeal swabs or bronchial aspirates by means of a molecular test by quantitative reverse transcription polymerase chain reaction (RT-qPCR). 13 This is a sensitive and specific method for detecting SARS-CoV-2, with different diagnostic protocols, including target primer sequences available in the WHO public database. 14 The test has its limitations since false negatives can be presented if the amount of viral genome is insufficient; also, it is estimated that the incubation period of COVID-19 is 5 days, and false negative results are common within 7 days afterwards the infection. In addition, the analyzes and studies of imaging and artificial intelligence (AI) have helped achieve a more accurate diagnosis, as well as the evaluation of patients during the monitoring of the therapy and treatment of COVID-19. 15, 16 Treatments in patients with COVID-19 are based on different combinations of medicines and treatment schemes (antiviral and/or immunotherapy and/or steroids) with a high potential for interactions, 17, 18 and one of the least evaluated effects is either the expression or the blocking of different drug-resistance genes. Some examples are the families of ABC membrane transporters (ATP-Binding Cassette) that include 49 different types of transporters, including the P-glycoprotein (P-gp). 19, 20 Their main function is cell detoxification, and are distributed along the hemato-encephalic barrier, placenta, kidney and liver. [21] [22] [23] The role of the expression of ABC genes in COVID-19 is still unknown, and various drugs used for COVID-19 may show some interaction with the ABC family, such as azithromycin (ABCB1), lopinavir/ritonavir (ABCC2) or antimalarial agents like chloroquine. 24, 25 In Mexico, the mortality associated with COVID-19 in severely ill patients is higher than expected due to a large extent by related risk factors. 26 Our working group has evaluated the impact of ABCB1 overexpression in patients with acute leukemia, which causes a decrease in survival. 27 The main objective of this study is to establish the impact of comorbidities, drugs used and the expression of ABCB1 gene on the overall survival and risk of death in COVID-19 patients.

This was an exploratory type study, performed during the second wave of COVID-19 in our country. All patients were in severe condition of intensive therapy, treated with different treatment schemes. Sixty-one patients with a diagnosis of COVID-19 admitted to the Intensive Care Unit of the General Hospital of Mexico¨Dr. Eduardo Liceaga¨were included, and their informed consent was obtained for the molecular analysis of the ABCB1 gene. The study was conducted in accordance with the Declaration of Helsinki. The project was approved by the Research, Ethics and Biosecurity Committees of the General Hospital of Mexico "Dr. Eduardo Liceaga" D1/15/103/03/57.

The expression levels of the ABCB1 gene were determined by RT-qPCR using gene-specific TaqMan™ hydrolysis probe (Hs01069047, Applied Biosystems, Inc. Foster City, CA, USA). Normalization was made with the endogen GUSB gene (Hs00939627). Each sample was analyzed in triplicate.

Relative expression levels were calculated using method 2 −ΔΔ Ct. The high and low expression cut-points were determined according to the average values observed in a previous study. 27 

The treatment of COVID-19 included the combination of high-flow oxygen with the best available therapy, according to the local recommendations and the time of recruitment. 8.2% (n = 5) initiated treatment with hydroxychloroquine, 44.3% (n = 27) with metformin hydrochloride, 36.1% (n = 22) with azithromycin, 55.7% (n = 34) with atorvastatin and 95.2% (n = 58) with low molecular weight heparin, all during the hospital period. 49.2% (n = 30) required ventilatory support, which modified the treatment according to each particular case, being mainly vasopressor drugs, sedation, analgesia, parenteral nutrition and anticoagulation therapy. No patient received Tocilizumab, convalescent plasma, nor plasma replacement. Only an individual in critical condition received Baricitinib for a short period of time. The average of hospital stay was 38.78 days, 57.4% died due to complications associated with COVID-19.

The association between the levels of expression, the risk variables and different treatments were determined by the Chi-Square test and the Fisher exact test. Global survival (GS) was determined by the Kaplan-Meier method. The impact of high levels of expression and the risk of death was performed through the odds ratio. The statistical software used was SPSS version 22.0.

A total of 61 patients diagnosed with COVID-19 were included, 59% corresponded to the male gender (n = 36), obesity was the most frequent comorbidity (45.9%, n = 28), followed by non-insulin-dependent diabetes (36.1%, n = 22) and hypertension (29.5%, n = 18). One-third of the patients had a history of smoking (32.8%) and about half of alcoholism (42.6%). The average of leukocytes when admitted was 13.1 × 10 3 /µL (3.1-55.4x10 3 /µL), 54.1% (n = 33) had leukocytosis at the time of diagnosis. Neutrophilia was reported by 77% (n = 47) and 65.6% (n = 40) counted with lymphopenia. Eosinopenia was constant, unlike thrombocytopenia (minor counts of 100x10 3 /µL) which was infrequent (3.3%). 74.3% (n = 52) had a neutrophil-lymphocyte index greater than 7 with an average of 18.1 (2 −123). The average of bilirubin was 0.42 mg/dL, 15.7% (n = 11) had bilirubin levels greater than 1.5 mg/dL. The average of albumin was 3.3 g/dL (1.7-4.1 g/dL), with 57.1% (n = 40) of individuals with hypoalbuminemia. No patient presented renal failure when admitted (Table 1 ). When we analyzed the expression levels of the ABCB1 gene in patients with COVID-19, we found that 37.7% (n = 23) had high levels, 36% (n = 22) low levels and for 26.2% (n = 16) It was absent. When evaluating the different risk factors such as diabetes, hypertension, smoking, alcohol consumption and overweight with respect to the expression levels of the ABCB1 gene, the results showed that alcohol consuming patients were associated with groups of patients expressing either high levels or absence of the ABCB1 gene (p ≤ 0.05, 95% CI). No association of risk factors was observed with respect to low levels of gene expression (Table 2) .

When analyzing the effect of the treatments used in patients with metformin, atorvastatin, hydroxychloroquine, azithromycin and anticoagulants, the results showed that groups of patients with high and negative levels of expression of the ABCB1 gene were associated with the use of atorvastatin and metformin (p ≤ 0.05, 95% CI), unlike low levels of gene expression ( It is important to note that patients with diabetes which were treated with metformin due to their condition were associated with a lower risk of death (OR 1.11.95% CI 0.38-3.22), as well as patients who presented low levels of expression of the ABCB1 gene (OR 0.34, 95% CI 011-1.08) Table 4 .

Finally, in the overall survival (OS) at 78 days of follow-up with respect to the expression levels of the ABCB1 gene, it was found that the high and absent expression groups showed an average of 11.18 days (9-13.37) and an OS of 33.3%, while those who presented low levels had an average of 67.42 days (56.3-78.7) and an OS of 59.1% (p = 0.00, Log Rank Test). Figure 1 . 

The COVID-19 has currently become the leading cause of death worldwide, causing a great economic and social crisis. The WHO has reported more than 462 million confirmed cases of SARS-CoV2 infection around the world with more than~6 million deaths. 28 Adverse drug reactions (ADR) associated with current treatments for COVID-19 are one of the main causes of death in patients with multiple comorbidities. 29, 30 In a recent pharmacovigilance study conducted in Spain, an incidence 4.75 times higher to present ADR in severe patients with COVID-19 compared to patients with some other condition and treated with azithromycin (8.4%), dexamethasone (7.6%), lopinavir-ritonavir (7.4%) and chloroquine (CQ)/hydroxychloroquine (HCQ) (6.9%) was reported. 31 Another study conducted in Brazil with 402 patients with COVID-19 indicated that chloroquine (CQ) (OR = 5.4, 95% CI: 1.9-15.6) and hydroxychloroquine (HCQ) (OR = 2.1 95% CI: 1.2-3.6) were the only drugs associated with severe ADR. 32 At present there are no specific therapeutic recommendations for the treatment of COVID-19. 29, 33 The treatment based on chloroquine, a drug used as immunosuppressor in lupus and rheumatoid arthritis, has shown an in vitro antiviral effect against influenza and different types of coronavirus, including COVID-19. 34, 35 When analyzing the available evidence, its use did not impact mortality, but it did increase the risk of complications, mainly cardiovascular. 36 Also, a drug widely used is azithromycin, which contributes to preventing the entry of the virus to the cell via CD147 with potential antiviral activity, and it is generally used in combination with hydroxychloroquine. 37, 38 Other drugs with immunomodulatory effect are statins and metformin hydrochloride, its use became a daily practice in our country due to the high prevalence of diabetes and obesity. 39, 40 It has been shown that a group of patients with COVID-19 suffering from chronic type 2 diabetes, being treated with metformin, increased their survival, which was associated with a lower risk of death. [41] [42] [43] In conjunction with anticoagulation and various anti-inflammatory drugs, the combination of these drugs was a fundamental part of the treatment for COVID-19 during the first months of pandemic in Mexico. We evaluated the expression levels of ABCB1 genes in COVID-19 patients and found high levels of expression, 37.7%. Several studies have shown that the expression levels of the mRNA are increased by the response to substrates of the ABCB1 pump, and within the substrates described are azithromycin and atorvastatin, as well as self-medicated antibiotics. 44 The use of these drugs would explain the increase in levels, unlike the healthy population. It is important to highlight that patients who presented high levels of expression mostly had associated comorbidities such as diabetes and hypertension, and most of them were of the male gender.

It has been previously demonstrated that the expression of the ABCB1 gene is altered in different metabolic diseases including diabetes. 45 When analyzing the risk factors of patients with COVID-19 associated with high levels of expression and absence of expression of ABCB1 gene, alcohol consumption was significant, this is consistent with the work of Haaman et al 2019, in which prolonged exposure to drug abuse, ethanol and cocaine alters the expression of ABCB1 mRNA. 46 When the impact of the different treatments was evaluated, we observed increased expression levels in patients who did not consume metformin. Metformin inhibits the expression of the NF-kB nuclear factor, inducing the apoptosis of hepatocytes and inhibiting the expression of the ABCB1 gene. 47, 48 Finally, the group of patients with either high levels or absence of expression of the ABCB1 gene showed a lower survival rate, unlike the group of patients with low levels. These results are very similar to other studies that explain that the increased expression of these genes is related to the expulsion of the drugs used in the treatments, and, therefore, the failure thereof and the absence of expression would be causing an intoxication with the drugs by not protecting against xenobiotic agents in the different tissues, which leads to an organic failure, and this agrees with the reported in other ailments. 49, 50 

The alteration in the expression of the ABCB1 gene is associated with an increased risk of death or progression of the disease; the failure of previous treatments can be explained by the interaction of the drugs with the flow pump, modifying its distribution in different tissues.

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; ABCB1, ATPbinding cassette B1; P-gp, P-glycoprotein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NF-kB, nuclear factor kappa B; OS, overall survival.

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Written informed consent was obtained from all subjects and the study was approved by the Ethics Committee of the Hospital General Mexico "Dr Eduardo Liceaga".

World Health Organization. WHO director-general's opening remarks at the media briefing on COVID-19 -11

Genomic characterization of a novel SARS-CoV-2

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

COVID-19 diagnosis -a review of current methods

A novel coronavirus from patients with pneumonia in China

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

The coronavirus and the risks to the elderly in long-term care

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China

Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study

Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19

Group testing for COVID-19: how to stop worrying and test more

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application

Exploring the potential of artificial intelligence and machine learning to combat COVID-19 and existing opportunities for LMIC: a scoping review

Artificial intelligence in surveillance, diagnosis, drug discovery and vaccine development against COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Transporter-mediated drug-drug interactions and their significance

ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development

ABC transporters as a multidrug detoxification mechanism in Rhipicephalus (Boophilus) microplus

Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation

ABC transporters and drug efflux at the blood-brain barrier

The interactions of p-glycoprotein with antimalarial drugs, including substrate affinity, inhibition and regulation

Pharmacogenomics of COVID-19 therapies

In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico city; causes of death, risk factors and the impact of hospital saturation

Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia

World Health Organization. WHO coronavirus (COVID-19) dashboard. (s. f.). With vaccination data

Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments

Incidence of adverse drug reactions in COVID-19 patients in China: an active monitoring study by hospital pharmacovigilance system

Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: cautionary data

Adverse drug reactions in patients with COVID-19 in Brazil: analysis of spontaneous notifications of the Brazilian pharmacovigilance system. Reações adversas a medicamentos em pacientes com COVID-19 no Brasil: análise das notificações espontâneas do sistema de farmacovigilância brasileiro

Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19

Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?

Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials

An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of hydroxychloroquine and chloroquine therapy

Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19

Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal

Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?

Metformin and COVID-19: a novel deal of an old drug

Risk of metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report

Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and other recent reports

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances

Association between ABC family variants rs1800977, rs4149313, and rs1128503 and susceptibility to type 2 diabetes in a Chinese Han population

Alcohol and cocaine exposure modulates ABCB1 and ABCG2 transporters in male alcohol-preferring rats

Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant mcf-7 breast cancer cells

Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene

Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis

Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use

The authors thank Direccion de Investigación Hospital General de Mexico.

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

This work was supported by the Direccion de Investigacion Hospital General Mexico "Dr Eduardo Liceaga" (DI/20/204/ 04/31, DI/20/204/04/41).

The authors declare that they have no competing interests.